Vepdegestrant Plus Palbociclib for Patients With ER-Positive, HER2-Negative Advanced Breast Cancer
Seth Wander, MD, PhD, Massachusetts General Hospital, discussed results from the phase 1b cohort of a phase 1/2 clinical trial which demonstrated that vepdegestrant plus palbociclib is clinically effective among patients with heavily pretreated, ER-positive, HER2-negative advanced breast cancer.
These results were first reported at the 2023 San Antonio Breast Cancer Symposium.
Source:
Hamilton E, Jeselsohn R, Hurvitz S, et al. Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: phase 1b cohort. Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9; San Antonio, Texas. Abstract PS15-03